Tuberculosis: A Review on Its Novel Advancement on Its Elimination
Dr.M.Shamshath Begum*, Dr.Deepa
Natarajan, Cathrina.A, Kokila.R, Dhanusri.J, Hyrun Laafiya.J.A,
Prince.Pinegah.K., Mageshwari.S, Rupavathi Christina.J
1.Professor and Head (Department of
Pharmaceutics) , Faculty of pharmacy, Sree Balaji Medical College and Hospital Campus, Bharat Institute of Higher
Education And Research (BIHER), Chromepet, Chennai-44 (TamilNadu).
2.Dean, Faculty of pharmacy, Sree Balaji Medical College and Hospital Campus, Bharat Institute of Higher Education and Research (BIHER), Chromepet, Chennai-44 (TamilNadu).
3.Students, Faculty of pharmacy, Sree Balaji Medical College and Hospital Campus, Bharat Institute of Higher Education and Research (BIHER), Chromepet, Chennai-44 (TamilNadu)
ABSTRACT
Tuberculosis, caused by Mycobacterium
tuberculosis, remains a global public health issue. Latent TB is an airborne
chronic disease; 46% of the world’s population is thought to be infected with
LTB. It is most prevalent in the lungs (pulmonary TB) but can also affect other
organs (extrapulmonary TB). Immunocompromised individuals, such as HIV-positive
individuals, are at much greater risk for active TB.M. tuberculosis is an
aerobic, non-motile rod whose high levels of lipids make it difficult to
diagnose and thus avoid the immune system. It is transmitted via aerosol
droplets, where the bacteria infect the lungs and can then remain in granulomas
for years. One of the major obstacles to TB control is the advent of
drug-resistant strains, such as multidrug-resistant TB, which are not effective
when compared to the best first-line agents. Toxic treatment, lack of quality
drugs, or improper medicine contribute to its growth. High levels of diagnostic
variability hinder progress, and an estimated 4 million undiagnosed cases a
year fuel transmission. WGS can be applied in various ways, but its use has a
limited impact. A financial constraint also severely limits TB control efforts.
Future strategies to combat TB will include better vaccines, new drugs and
rapid point-of-care diagnostics. Controlling the disease requires focused
screening practices, diagnosis intervention, adequate funding, and drug
resistance, along with ethical principles of informed consent and patient
agency in research and care.
Keywords: Mycobacterium
tuberculosis, drug-resistant, novel drug discovery, TB preventive therapy and
screening practices